BCL-2 AND P53 EXPRESSION IN CLINICALLY LOCALIZED PROSTATE CANCER PREDICTS RESPONSE TO EXTERNAL BEAM RADIOTHERAPY
- 1 July 1999
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 162 (1), 12-17
- https://doi.org/10.1097/00005392-199907000-00003
Abstract
Purpose: Clinicians have long been hampered by the inability to distinguished patients with localized prostate cancer who will and will not respond to radiotherapy. In a significant proportion of patients therapy fails as determined by increasing posttreatment serum prostate specific antigen (PSA). We evaluated the expression of 2 key regulators of apoptosis, bcl-2 and p53, relative to treatment outcomes in patients who received external beam radiotherapy for clinically organ confined carcinoma of the prostate. Materials and Methods: Immunohistochemical staining for bcl-2 and p53 on pretreatment needle biopsies was performed in 54 patients who were treated with radiotherapy for localized prostate cancer. Expression was scored using strict criteria. Nadir PSA less than 1 ng./ml. after therapy was considered a successful treatment response. Results: There was a predominance of stage T1c cancer (74%) with a mean Gleason score of 6.9 and an average pretreatment PSA of 25.3 ng./ml. Overall 54% of the patients did not have a nadir PSA of less than 1 ng./ml. Of the bcl-2 positive cases therapy ultimately failed in 85%. Similarly 88% of the patients with p53 positive biopsies had treatment failure and in all with bcl-2 as well as p53 expression radiotherapy failed. Expression of bcl-2 and p53 was an independent prognostic variable for treatment failure with odds ratios (95% confidence interval) of 7.3 and 10.8, respectively. Conclusions: Expression of bcl-2 and p53 was associated with treatment failure after external beam radiation therapy. These findings suggest that bcl-2 and p53 expression in pretreatment biopsies may be helpful for predicting response to definitive radiotherapy.Keywords
This publication has 27 references indexed in Scilit:
- Different pathways for radiation-induced apoptosisInternational Journal of Radiation Oncology*Biology*Physics, 1997
- Bcl-2 and Bax function independently to regulate cell deathNature Genetics, 1997
- The proto-oncogene Bcl-2 and its role in regulating apoptosisNature Medicine, 1997
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updateJAMA, 1997
- Changes in Biomarker Expression in the Development of Prostatic AdenocarcinomaBiotechnic & Histochemistry, 1997
- Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate CancerJournal of Urology, 1996
- Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancerSurgery, 1996
- Radiation therapy for prostate cancer long-term results and implications for future advancesCancer, 1993
- p53 function and dysfunctionCell, 1992
- Radical Prostatectomy for Stage a Adenocarcinoma of the Prostate: Staging Errors and their Implications for Treatment Recommendations and Disease OutcomeJournal of Urology, 1991